Overall, we found that alpha-1-antitrypsin (A1AT) deficiency was present in 10.8% of patients with biliary tract cancer (BTC), a higher rate than the general population, and seemed to be associated with specific clinicopathological features. This evidence concerns the gene SERPINA1 and biliary tract neoplasm.